Obesity and sexual function

Krychman, Michael

doi:10.1097/gme.0000000000000539

Cited by 6 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among patients who chose follow up cervical cytology, remission rate of pre (Chen et al, 2018). From the present study, postmenopausal women were more likely to be obese and have underlying diseases including diabetes mellitus, hypertension and cardiovascular disease, similar to the findings reported in previous literature (Krychman et al, 2015). According to 2003-2012 National Health and Nutrition Examination Survey (NHANES) data, metabolic syndrome presented in about 34 percent of the population and the rates of metabolic syndrome were increasing among postmenopausal women (Chen et al, 2018).…”

Section: Discussionsupporting

confidence: 88%

Effect of Obesity in Persistent or Remission in Postmenopausal Women with Atypical Cervical Cytology

Phaliwong

Luangdansakul

Bhamarapravatana

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Hav et al., 2016). It is known that the cervical cytology of the ASC-US type is an atypical report that indicated either a low-risk or high grade cervical cytology abnormality. AbstractObjectives: To determine the effects of obesity in pre and postmenopausal women diagnosed with atypical squamous cells of undetermined significance (ASC-US) (in cases of remission, persistence, and progression of disease) after initial management and follow-up within 2 years to inform proper management for postmenopausal Thai women. Methods: This retrospective study was conducted at Bhumibol Adulyadej Hospital, Thailand between January 2013 and October 2018. Medical records of 506 patients whose cervical cytology reported of ASC-US were reviewed. Prevalence of silent high grade cervical intraepithelial neoplasia (CIN2/3) was evaluated. Cervical cytology after completed follow-up within 2 years were determined. Results: During the study period, there were 506 cases of ASC-US cytology reported. One quarter of cases were of post-menopausal status. Prevalence of CIN 2/3 in ASC-US cytology in pre and postmenopausal women were 9.9 and 7.2%, respectively. At 2-year follow-up appointments, around 90% of patients who completed follow-up remained in remission of the disease in both age groups. Menopausal status, body mass index (BMI), sexual activity, number of sexual partners, parity, smoking and hormone replacement therapy were not correlating factors to remission. Obese postmenopausal women had a lower remission rate of CIN, but this finding was not statistically significant. Conclusion: Obesity was not found to correlate strongly with the progression or remission of CIN. Obese postmenopausal women may still be affected by a persistence of the disease. Continuing cervical cytology monitoring should be recommended for such patients. Silent high grade cervical intraepithelial neoplasia (CIN2/3) in ASC-US cytology in this study were high. Colposcopy should be recommended for diagnosis and follow-up in this setting.

show abstract

Section: Discussionsupporting

confidence: 88%

Effect of Obesity in Persistent or Remission in Postmenopausal Women with Atypical Cervical Cytology

Phaliwong

Luangdansakul

Bhamarapravatana

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…Favorable effects of lasofoxifene (0.5 mg/d) on hypoactive sexual desire disorder independent of VVA symptoms were observed in a randomized, placebo-controlled, phase 2, proof-of-concept study in postmenopausal women with acquired hypoactive sexual desire disorder after 6 months of treatment 44 . Another phase 2, osteoporosis prevention study showed that lasofoxifene (0.25 or 1 mg/d) increased sexual activity ( P = 0.077) and orgasm ( P = 0.006) compared with placebo in postmenopausal women after 12 months of treatment, while raloxifene did not provide any significant effects 45 . These previous findings in conjunction with the current phase 3 data support that lasofoxifene may improve sexual function in postmenopausal women by improving the signs and symptoms of VVA.…”

Section: Discussionmentioning

confidence: 99%

Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials

Kagan,

Simon,

Goldstein

et al. 2024

Menopause

View full text Add to dashboard Cite

Objective The aim of this study was to demonstrate whether lasofoxifene improves vaginal signs/symptoms of genitourinary syndrome of menopause. Methods Two identical, phase 3 trials randomized postmenopausal women with moderate to severe vaginal symptoms to oral lasofoxifene 0.25 or 0.5 mg/d, or placebo, for 12 week. Changes from baseline to week 12 in most bothersome symptom, vaginal pH, and percentages of vaginal parabasal and superficial cells were evaluated. These coprimary endpoints were analyzed using analysis of covariance, except superficial cells, which were analyzed by the nonparametric, rank-based Kruskal-Wallis test. Results The two studies enrolled 444 and 445 women (mean age, ~60 y), respectively. Coprimary endpoints at week 12 improved with lasofoxifene 0.25 and 0.5 mg/d greater than with placebo (P < 0.0125 for all). Study 1: most bothersome symptom (least square mean difference from placebo: −0.4 and −0.5 for 0.25 and 0.5 mg/d, respectively), vaginal pH (−0.65, −0.58), and vaginal superficial (5.2%, 5.4%), and parabasal (−39.9%, −34.9%) cells; study 2: most bothersome symptom (−0.4, −0.5), vaginal pH (−0.57, −0.67), and vaginal superficial (3.5%, 2.2%) and parabasal (−34.1%, −33.5%) cells. Some improvements occurred as early as week 2. Most treatment-emergent adverse events were mild or moderate and hot flushes were most frequently reported (lasofoxifene vs placebo: 13%–23% vs 9%–11%). Serious adverse events were infrequent and no deaths occurred. Conclusions In two phase 3 trials, oral lasofoxifene 0.25 and 0.5 mg/d provided significant and clinically meaningful improvements in vaginal signs/symptoms with a favorable safety profile, suggesting beneficial effects of lasofoxifene on genitourinary syndrome of menopause.

show abstract

Pelvic floor dysfunctions and associated factors in female CrossFit practitioners: a cross-sectional study

2020

View full text Add to dashboard Cite

Obesity and sexual function

Cited by 6 publications

References 15 publications

Effect of Obesity in Persistent or Remission in Postmenopausal Women with Atypical Cervical Cytology

Effect of Obesity in Persistent or Remission in Postmenopausal Women with Atypical Cervical Cytology

Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials

Pelvic floor dysfunctions and associated factors in female CrossFit practitioners: a cross-sectional study

Contact Info

Product

Resources

About